CompletedNot Applicable

Ten-Year Biologic Drug Survival in Psoriasis: Role of Genetic and Cardiometabolic Predictors

Spain1,000 participantsStarted 2012-01-01

Plain-language summary

This retrospective observational study aims to evaluate the long-term survival of biologic therapies in adult patients with moderate-to-severe cutaneous psoriasis, with or without psoriatic arthritis, over a period of up to 10 years. The study investigates the influence of clinical, metabolic, and genetic factors, including SNPs and metabolic syndrome components, on treatment durability. Data were obtained from a single-centre cohort treated in routine clinical practice. This analysis seeks to identify predictors of therapeutic response and to explore pharmacogenetic profiles that may inform personalized treatment strategies.

Who can participate

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Adults (≥18 years) diagnosed with moderate-to-severe cutaneous psoriasis. * Initiation of treatment with a biologic agent between 2010 and 2020. * Minimum follow-up of 12 months or until drug discontinuation. * Availability of clinical and treatment data at baseline. * Availability of at least one blood sample for biomarker/genetic analysis. * Informed consent obtained for biobanking and genetic analyses. Exclusion Criteria: * Diagnosis of other chronic inflammatory skin diseases (e.g., atopic dermatitis, lupus). * Concomitant participation in interventional clinical trials at baseline. * Patients with incomplete treatment history or missing survival data. * Systemic immunosuppressive therapy (e.g., cyclosporine, methotrexate) without biologics during the study period.

What they're measuring

Drug survival at 10 years

Timeframe: Up to 10 years from treatment start

Trial details

NCT IDNCT07041112

SponsorJuan Ruano Ruiz

Sponsor typeOTHER

Study typeOBSERVATIONAL

Primary completion2023-03-01